Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05836987 · ClinicalTrials.gov registry record · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
A Phase 3 study of Atrial Fibrillation, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 5,350
- Enrollment target
- 20
- Study locations
NCT05836987: Recruiting Phase 3 study of Atrial Fibrillation, sponsored by Johns Hopkins University.
NCT05836987 is a Phase 3 study of Atrial Fibrillation that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 5,350 participants, above the 2,970-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (80% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05836987, a Phase 3 study of Atrial Fibrillation, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 5,350 participants
- Enrollment target
- 20
- Study locations
Study Summary
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Primary Outcome
The primary objective (efficacy objective) of the REACT-AF trial is to assess whether AFSW-guided, time-delimited DOAC therapy is non-inferior to continuous DOAC therapy for a composite endpoint that includes: (1) Ischemic stroke; (2) Systemic embolism; and (3) All-cause mortality. Stroke is defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction; and classified as ischemic, hemorrha
Conditions Studied
Interventions
- DEVICE AFSW Guided DOAC
- DRUG Continuous DOAC therapy
Study Locations (20)
Florida
- BayCare Health Systems - Clearwater
- University of Florida - Gainesville
- Mayo Clinic - Jacksonville
- University of Miami - Leonard S. Miller SOM - Miami
- Sarasota Memorial Health Care System - Sarasota
- Cleveland Clinic Florida - Stuart
- Baycare Health Systems Clearwater - Winter Haven
California
- University of Southern California - Keck School of Medicine - Los Angeles
- University of California Los Angeles (UCLA Health) - Los Angeles
- UC Davis Health - Sacramento
- Scripps Health - San Diego
- Stanford University - Stanford
Colorado
- University of Colorado - Aurora
- South Denver Cardiology Associates, P.C. - Littleton
District of Columbia
- St. Elizabeth's Medical Center - Washington D.C.
- Medical Faculty Associates George Washington University - Washington D.C.
Georgia
- Emory University - Atlanta
- Georgia Arrhythmia Consultants and Research Institute - Warner Robins
Arizona
- Banner University - Phoenix
Illinois
- University of Illinois Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,350 participants |
| Start Date | 2023-07-13 |
| Est. Completion | 2029-07-31 |
| Phase | Phase 3 |
What NCT05836987 shows while recruiting
NCT05836987 is an interventional study that assigns participants to a tested intervention. Its 5,350 participants enrollment target places it among the larger protocols in the corpus, above the 2,970-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (80% higher).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which AFSW Guided DOAC is the first listed.
NCT05836987 names 20 study sites across 7 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05836987 about?
NCT05836987 is a clinical study titled "The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation". REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in partic...
What is the current status of trial NCT05836987?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,350 participants. The study started on 2023-07-13. Estimated completion is 2029-07-31.
What conditions does trial NCT05836987 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT05836987?
The interventions under investigation include: AFSW Guided DOAC (DEVICE), Continuous DOAC therapy (DRUG).
Who is sponsoring clinical trial NCT05836987?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05836987 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05836987's enrollment target sits among peer trials
5,350 16th of 202 higher than 187 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373771 · 5,328 participants · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
- NCT04295486 · 5,478 participants · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI